{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"eVOLVE-Lung02","nct_id":"NCT05984277","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=evolve-lung02-nct05984277. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"eVOLVE-Lung02","arms":[{"description":"Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Pembrolizumab plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion","label":"Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-11-12","type":"ESTIMATED"},"conditions":["Metastatic Non-small Cell Lung Cancer"],"enrollment":{"count":895,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Volrustomig","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"}],"last_update":"2026-10-09","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)","timeFrame":"Up to approximately 6 years"},{"measure":"Overall Survival (OS), in PD-L1-negative participants.","timeFrame":"Up to approximately 6 years"}],"references":[],"start_date":{"date":"2023-10-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.","url":"https://clinicaltrials.gov/study/NCT05984277"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/evolve-lung02-nct05984277"}